Sinopharm Group Co Stock Buy Hold or Sell Recommendation
| SHTDF Stock | USD 2.35 0.00 0.00% |
Roughly 62% of Sinopharm Group's investor base is looking to short. The analysis of overall sentiment of trading Sinopharm Group Co pink sheet suggests that many investors are alarmed at this time. The current market sentiment, together with Sinopharm Group's historical and current headlines, can help investors time the market. In addition, many technical investors use Sinopharm Group stock news signals to limit their universe of possible portfolio assets.
Comfort Level 38
Alarmed
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Sinopharm Group's input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Sinopharm Group Co.
News SentimentNeutral | Hype SentimentBearish | Insider SentimentWaiting |
Assuming the 90 days horizon and your slightly conservative level of risk, our recommendation regarding Sinopharm Group Co is 'Strong Sell'. Macroaxis provides Sinopharm Group buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding SHTDF positions.
Execute Sinopharm Group Buy or Sell Advice
The Sinopharm recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Sinopharm Group Co. Macroaxis does not own or have any residual interests in Sinopharm Group Co or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Sinopharm Group's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Weakest | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Moves indifferently to market moves | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Inapplicable | Details |
Sinopharm Group Trading Alerts and Improvement Suggestions
| Sinopharm Group generated a negative expected return over the last 90 days |
Sinopharm Group Returns Distribution Density
The distribution of Sinopharm Group's historical returns is an attempt to chart the uncertainty of Sinopharm Group's future price movements. The chart of the probability distribution of Sinopharm Group daily returns describes the distribution of returns around its average expected value. We use Sinopharm Group Co price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Sinopharm Group returns is essential to provide solid investment advice for Sinopharm Group.
| Mean Return | 0.04 | Value At Risk | 0.00 | Potential Upside | 1.20 | Standard Deviation | 1.50 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Sinopharm Group historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Sinopharm Group Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Sinopharm Group or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Sinopharm Group's price will be affected by overall pink sheet market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Sinopharm pink sheet's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.03 | |
β | Beta against Dow Jones | -0.01 | |
σ | Overall volatility | 1.07 | |
Ir | Information ratio | -0.02 |
Sinopharm Group Volatility Alert
Sinopharm Group Co exhibits very low volatility with skewness of 2.01 and kurtosis of 20.4. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Sinopharm Group's pink sheet risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Sinopharm Group's pink sheet price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Sinopharm Group Fundamentals Vs Peers
Comparing Sinopharm Group's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Sinopharm Group's direct or indirect competition across all of the common fundamentals between Sinopharm Group and the related equities. This way, we can detect undervalued stocks with similar characteristics as Sinopharm Group or determine the pink sheets which would be an excellent addition to an existing portfolio. Peer analysis of Sinopharm Group's fundamental indicators could also be used in its relative valuation, which is a method of valuing Sinopharm Group by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Sinopharm Group to competition |
| Fundamentals | Sinopharm Group | Peer Average |
| Return On Equity | 0.13 | -0.31 |
| Return On Asset | 0.0364 | -0.14 |
| Profit Margin | 0.01 % | (1.27) % |
| Operating Margin | 0.04 % | (5.51) % |
| Current Valuation | 16.78 B | 16.62 B |
| Shares Outstanding | 1.34 B | 571.82 M |
| Shares Owned By Insiders | 0.01 % | 10.09 % |
| Shares Owned By Institutions | 51.07 % | 39.21 % |
| Price To Earning | 5.67 X | 28.72 X |
| Price To Book | 0.88 X | 9.51 X |
| Price To Sales | 0.01 X | 11.42 X |
| Revenue | 521.05 B | 9.43 B |
| Gross Profit | 44.05 B | 27.38 B |
| EBITDA | 20.76 B | 3.9 B |
| Net Income | 7.76 B | 570.98 M |
| Cash And Equivalents | 32.15 B | 2.7 B |
| Cash Per Share | 10.30 X | 5.01 X |
| Total Debt | 8.42 B | 5.32 B |
| Debt To Equity | 0.89 % | 48.70 % |
| Current Ratio | 1.31 X | 2.16 X |
| Book Value Per Share | 21.01 X | 1.93 K |
| Cash Flow From Operations | 9.31 B | 971.22 M |
| Earnings Per Share | 0.37 X | 3.12 X |
| Price To Earnings To Growth | 49.02 X | 4.89 X |
| Number Of Employees | 113.23 K | 18.84 K |
| Beta | 0.72 | -0.15 |
| Market Capitalization | 8.94 B | 19.03 B |
| Total Asset | 335.41 B | 29.47 B |
| Retained Earnings | 11.43 B | 9.33 B |
| Working Capital | 32.26 B | 1.48 B |
| Current Asset | 130.51 B | 9.34 B |
| Current Liabilities | 98.25 B | 7.9 B |
| Z Score | 1.6 | 8.72 |
Sinopharm Group Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Sinopharm . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Sinopharm Group Buy or Sell Advice
When is the right time to buy or sell Sinopharm Group Co? Buying financial instruments such as Sinopharm Pink Sheet isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Sinopharm Group in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Israel Wall Street Thematic Idea Now
Israel Wall Street
Cross-sector collection of best publicly traded Israel entities that are expected to continue growing. The Israel Wall Street theme has 30 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Israel Wall Street Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Sinopharm Pink Sheet
Sinopharm Group financial ratios help investors to determine whether Sinopharm Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Sinopharm with respect to the benefits of owning Sinopharm Group security.